araag2/HINT huggingface dataset:
Clinical trial NCT00296972 (phase 3, status: terminated)
Conditions: chronic hepatitis c, hiv infections
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4, Z21
Drugs: peg interferon plus ribavirin
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Reason stopped: 
    not funded
  
Eligibility criteria:

        Inclusion Criteria:

          -  Hepatitis C genotype 1 infection·

          -  Detectable plasma HCV-RNA Roche>1000copies/ml, >600IU/ml

          -  Chronic liver disease consistent with CHC infection on a biopsy obtained within the
             past 24 months

          -  Patients with cirrhosis or incomplete cirrhosis must have an abdominal ultrasound, CT
             scan, or MRI scan without evidence of hepatocellular carcinoma and a serum AFP <100
             ng/mL within 2 months of randomization

          -  Patients with CD4 cell count ³ 350 cells /µL

          -  Patients on stable highly active antiretroviral therapy (HAART) for at least 12 weeks
             prior to baseline with the exception of patients receiving didanosine

          -  HIV-1 RNA is < 5000 copies/mL

        Exclusion Criteria:

          -  IFN, pegylated interferons, viramidine, levovirin, or ribavirin therapy at any
             previous time

          -  Patients with evidence of active hepatitis B infection. ( presence of HbsAg)

          -  History or evidence of decompensated liver disease and/or a Child-Pugh score > 5,
             bleeding from esophageal varices, hepatic malignancy

          -  abnormal bloodwork ie absolute neutrophil <1,Hbg <110, Platelets <70,creatinine <50
Clinical trial NCT00119756 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: paliperidone palmitate
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  The patient must have signed an informed consent

          -  The patient must meet the diagnostic criteria for schizophrenia

          -  Female patient must be postmenopausal for at least 2 years or have negative pregnancy
             test result at screening

          -  The patient must be able to perform study requirements (e.g. answer questionnaire)

        Exclusion Criteria:

          -  Primary, active diagnosis other than schizophrenia

          -  Psychiatric inpatient hospitalization for relapse of symptoms of schizophrenia in the
             past 90 days

          -  Change in their antipsychotic medication in the past 45 days

          -  Diagnosis of active substance dependence within 3 months

          -  History of treatment resistance

          -  History of concurrent significant or unstable diseases (e.g. heart, lung, or liver
             diseases)
Clinical trial NCT00575055 (phase 3, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: bapineuzumab 0.5 mg/kg, placebo control, bapineuzumab 1.0 m/kg
SMILES: CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of probable AD

          -  Age from 50 to less than 89

          -  Mini-Mental Status Exam score of 16-26 inclusive

          -  Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD

          -  Stable doses of medications (cholinesterase inhibitors and memantine allowed)

          -  Caregiver able to attend all clinic visits with patient

        Exclusion Criteria:

          -  Significant neurological disease other than AD

          -  Major psychiatric disorder

          -  Significant systemic illness

          -  History of stroke or seizure, autoimmune disease, myocardial infarction within the
             last 2 years

          -  Smoking greater than 20 cigarettes per day

          -  Anticonvulsants, anti-Parkinson's, anticoagulant, or narcotic medications

          -  Prior treatment experimental immunotherapeutics or vaccines for AD

          -  Women of childbearing potential

          -  Presence of pacemakers, CSF shunts, or foreign metal objects in the eyes, skin or body
Clinical trial NCT01222520 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: telmisartan and amlodipine, telmisartan
SMILES: CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O, CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion criteria:

          -  Essential hypertensive patients

               -  If already taking antihypertensive drugs, mean seated diastolic blood pressure
                  (DBP) must be >=90 and >=114 mmHg

               -  If not taking any antihypertensive drugs, mean seated DBP must be >=95 and >=114
                  mmHg

          -  Able to stop all current antihypertensive drugs without risk to the patient based on
             the investigators opinion.

        Exclusion criteria:

          -  Patients taking 3 or more antihypertensive drugs at signing the informed consent form

          -  Patients with known or suspected secondary hypertension

          -  Patients with clinically relevant cardiac arrhythmia

          -  Congestive heart failure with New York Heart Association (NYHA) functional class
             III-IV

          -  Patients with recent cardiovascular events

          -  Patients with a history of stroke or transient ischaemic attack within last 6 months
             before signing the informed consent form

          -  Patients with a history of sudden deterioration of renal function with angiotensin II
             receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors; or
             patients with post-renal transplant or post-nephrectomy

          -  Patients who have previously experienced characteristic symptoms of angioedema (such
             as facial, tongue, pharyngeal, or laryngeal swelling with dyspnea) during treatment
             with ARBs or ACE inhibitors

          -  Patients with known hypersensitivity to any component of the investigational product,
             or a known hypersensitivity to dihydropyridine-derived drugs

          -  Patients with hepatic and/or renal dysfunction

          -  Pre-menopausal women who are nursing or pregnant
Clinical trial NCT00300456 (phase 3, status: completed)
Conditions: dyslipidemia, coronary heart disease, mixed dyslipidemia
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: abt-335, simvastatin, placebo
SMILES: CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1, CC1=CC(O)=CC(C)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with mixed dyslipidemia

          -  Subjects agree to utilize adequate birth control methods and to adhere to the American
             Heart Association (AHA) diet.

        Exclusion Criteria:

          -  Subjects with unstable medical conditions or medical conditions considered
             inappropriate in a clinical trial.

          -  Patients who are taking certain medications or unstable dose of specific medications.

          -  Women who are pregnant or plan on becoming pregnant, or women who are lactating.
Clinical trial NCT00300885 (phase 3, status: terminated)
Conditions: carcinoma, non-small cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: nexavar (sorafenib, bay43-9006) + carboplatin + paclitaxel, carboplatin plus paclitaxel
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    based on the results of the interim analysis, it was determined that the study would not meet
    its primary efficacy endpoint and the study was terminated early.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Stage IIIB (with effusion) or Stage IV NSCLC any histology

          -  No prior chemotherapy

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  Greater than or equal to 18 years of age

          -  Life expectancy at least 12 weeks

          -  Adequate bone marrow, liver and renal function

        Exclusion Criteria:

          -  Prior systemic anti cancer therapy

          -  Known brain metastasis. Patients with neurological symptoms should undergo at computed
             tomography (CT) scan/magnetic resonance imaging (MRI) of the brain to exclude brain
             metastasis

          -  Pulmonary hemorrhage/bleeding event > Common Terminology Criteria for Adverse Events
             (CTCAE) Grade 2 within 4 weeks of first dose of study drug

          -  Thrombotic or embolic events including Transient ischemic attack (TIA) within the past
             6 months

          -  Uncontrolled hypertension

          -  Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of
             study drug

          -  Major surgery within 4 weeks

          -  Evidence or history of bleeding diathesis or coagulopathy
Clinical trial NCT00105196 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: aripiprazole+ adt, placebo+ adt
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women, 18-65 years old who have experienced single or recurrent, non-psychotic
             episodes of Major Depressive Disorder, with the current episode of minimally 8 weeks
             in duration.

          -  Treatment history of an inadequate response to at least one and no more than three
             adequate antidepressant trials.
Clinical trial NCT00494013 (phase 3, status: completed)
Conditions: diabetes mellitus type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin lispro protamine suspension, detemir
SMILES: OC(=O)[C@@H]1CCCN1
Eligibility criteria:

        Inclusion Criteria:

          1. Have type 2 diabetes mellitus for at least 1 year.

          2. Are at least 18 years old.

          3. Have been receiving oral antihyperglycemic medications (OAMs), without insulin, for at
             least 3 months immediately prior to the study and have been on stable doses of at
             least 2 of the following OAMs for the 6 weeks prior to Visit 1, at or above the doses
             defined in the following: Metformin--1500 milligrams per day (mg/day);
             Sulfonylureas--1/2 the maximum daily dose, according to the local package insert;
             Dipeptidyl peptidase-intravenous (DPP-IV) inhibitors-- 1/2 the maximum daily dose,
             according to the local package insert; Thiazolidinediones (TZDs)--30 mg/day
             pioglitazone or 4 mg/day rosiglitazone.

          4. Have a hemoglobin A1c (HbA1c) greater than or equal to 7.5% and less than or equal to
             10.0%, as measured by a central laboratory before Visit 2.

          5. Body mass index (BMI) greater than or equal to 25 and less than or equal to 45
             kilograms per square meter (kg/m2).

        Exclusion Criteria

          1. Have used insulin therapy (outside of pregnancy) any time in the past 2 years, except
             for short-term treatment of acute conditions, and up to a maximum of 4 weeks.

          2. Have taken any glucose-lowering medications not included in Inclusion Criterion [3]
             (for example, acarbose, miglitol, pramlintide, exenatide, repaglinide, or nateglinide)
             in the past 3 months before Visit 1.

          3. Have had more than 1 episode of severe hypoglycemia, within 6 months prior to entry
             into the study, or is currently diagnosed as having hypoglycemia unawareness.

          4. Have a history of renal transplantation or are currently receiving renal dialysis or
             creatinine greater than or equal to 2.0 milligrams per deciliter (mg/dL) (177
             micromoles per liter [micromol/L]).

          5. Have obvious clinical signs or symptoms, or laboratory evidence, of liver disease
             (alanine transaminase [ALT], or aspartate transaminase [AST] greater than 2 times the
             upper limit of the reference range, as defined by the local laboratory) or have
             albumin value above or below the normal reference range, as defined by the local
             laboratory.
Clinical trial NCT00723450 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: lamictal
SMILES: NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
Eligibility criteria:

        Inclusion Criteria

          -  Subject is male or female between the ages of 10 and 17 years, inclusive.

          -  Subject has a diagnosis of bipolar I disorder and is currently experiencing a
             manic/hypomanic, depressed, or mixed mood episode

          -  Subject is currently receiving a stable treatment regimen.

          -  Subject is living with his/her custodial parent(s) or legal guardian(s) and has
             contact with them on a daily basis.

        Exclusion Criteria

          -  Subject has been diagnosed with a primary Axis I disorder (with the exception of
             bipolar I disorder, ADHD, anxiety disorders, oppositional defiant disorder, or conduct
             disorder) or any Axis II disorder.

          -  Subject currently has signs or symptoms of psychosis or a history of psychosis within
             the previous four weeks.

          -  Subject has been diagnosed with epilepsy, autism, Asperger's syndrome, or Tourette's
             syndrome.

          -  Subject has experienced a serious rash, such as Stevens-Johnson Syndrome or Toxic
             Epidermal Necrolysis, or a rash otherwise requiring hospitalization.

          -  Subject has experienced a rash related to prior LAMICTAL use, or for whom LAMICTAL
             treatment was discontinued for clinically significant safety reasons.

          -  Subject has received any antidepressant medication, or atomoxetine, during the four
             weeks prior to the Screen Visit.

          -  Subject has initiated psychotherapy within 2 months prior to the Screen Visit, or
             plans to initiate psychotherapy during the trial.

          -  Subject in the 10-12 year old age group has a Body Mass Index (BMI) less than or equal
             15 or greater than or equal to 30; a subject in the 13-17 year old age group has a BMI
             less than or equal to 17 or greater than or equal to 34.

          -  Subject tests positive for illicit drug use at the Screen Visit, has a history of
             alcohol or substance abuse or dependence (other than nicotine dependence) within the
             past three months, or has a positive blood alcohol level at the Screen Visit.

          -  Subject, in the investigator's judgment, poses a current homicidal or serious suicidal
             risk, has made a suicide attempt within the twelve months preceding the Screen Visit,
             has ever been homicidal.
Clinical trial NCT00643201 (phase 3, status: completed)
Conditions: venous thrombosis
ICD codes: K64.5, I67.6, O87.3, O22.50, O22.51, O22.52, O22.53
Drugs: enoxaparin, warfarin, placebo for apixaban, placebo for enoxaparin, placebo for warfarin, apixaban
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], S1SSSSSSS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women ≥ 18 years of age

          -  Clinical diagnosis of DVT or PE

        Exclusion Criteria:

          -  Contraindications for enoxaparin or warfarin

          -  Active bleeding or high risk for serious bleeding

          -  Short life expectancy

          -  Uncontrolled high blood pressure

          -  Significantly impaired kidney or liver function
Clinical trial NCT00443209 (phase 3, status: completed)
Conditions: migraine
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: telcagepant 300 mg soft gel capsules, telcagepant 280 mg tablets, rizatriptan 10 mg tablets, placebo to telcagepant capsules, placebo to telcagepant tablets, placebo to rizatriptan tablets
SMILES: [H][C@]1(CC[C@@]([H])(N=C(O)N2CCC(CC2)N2C(O)=NC3=C2C=CC=N3)C(=O)N(CC(F)(F)F)C1)C1=C(F)C(F)=CC=C1, [H][C@]1(CC[C@@]([H])(N=C(O)N2CCC(CC2)N2C(O)=NC3=C2C=CC=N3)C(=O)N(CC(F)(F)F)C1)C1=C(F)C(F)=CC=C1, CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2, [H][C@]1(CC[C@@]([H])(N=C(O)N2CCC(CC2)N2C(O)=NC3=C2C=CC=N3)C(=O)N(CC(F)(F)F)C1)C1=C(F)C(F)=CC=C1, [H][C@]1(CC[C@@]([H])(N=C(O)N2CCC(CC2)N2C(O)=NC3=C2C=CC=N3)C(=O)N(CC(F)(F)F)C1)C1=C(F)C(F)=CC=C1, CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2
Eligibility criteria:

        Inclusion Criteria:

          -  At least 1 year history of migraine (with or without aura)

          -  Females of child bearing potential must use acceptable contraception throughout trial

          -  In general good health based on screening assessment

        Exclusion Criteria:

          -  Pregnant/breast-feeding (or is a female expecting to conceive during study period)

          -  History or evidence of stroke/transient ischemic attacks, heart disease, coronary
             artery vasospasm, other significant underlying cardiovascular diseases, uncontrolled
             hypertension (high blood pressure), uncontrolled diabetes, or human immunodeficiency
             virus (HIV) disease

          -  Major depression, other pain syndromes that might interfere with study assessments,
             psychiatric conditions, dementia, or significant neurological disorders (other than
             migraine)

          -  History of gastric, or small intestinal surgery, or has a disease that causes
             malabsorption

          -  History of cancer within the last 5 years
Clinical trial NCT01059344 (phase 3, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: mesalamin
SMILES: NC1=CC(C(O)=O)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

        (1) Male or non-pregnant, non-lactating females, 18 years of age or older. (2) Documented
        diagnosis of UC with disease extending at least 15 cm from the anal verge.

        (3) Active UC defined by:

        (a) modified UC-DAI score of 4-10 with (b) sigmoidoscopy component score ≥ 2 and (c) rectal
        bleeding component score ≥ 1 (4) Ability of subject to participate fully in all aspects of
        this clinical trial.

        (5) Written informed consent must be obtained and documented.

        Exclusion Criteria:

          1. Severe UC defined by the following criteria:

             ³6 bloody stools daily with one or more of the following:

               1. oral temperature > 37.8°C or > 100.0°F

               2. pulse > 90/min

               3. hemoglobin < 10 g/dL

          2. Previously failed treatment with a mesalazine dose of > 2.0 g/day.

          3. Current relapse lasting > 6 weeks in the opinion of the investigator.

          4. Treatment with 5-ASA at a dose of >2.0g/day within 1 week prior to randomisation

          5. Treatment with systemic or rectal steroids within 4 weeks prior to randomization.

          6. Treatment with immunosuppressants within 6 weeks prior to randomization.

          7. Treatment with infliximab or other biologics within 3 months prior to randomization.

          8. Treatment with systemic antibiotics for UC within 7 days prior to randomization.

          9. Treatment with probiotics within 7 days prior to randomization.

         10. Treatment with anti-diarrheals within 7 days prior to randomization.

         11. Treatment with nicotine patch within 7 days prior to randomization.

         12. Received any investigational drug within 30 days prior to randomization.

         13. History of colectomy or partial colectomy.

         14. History of definite dysplasia in colonic biopsies.

         15. Crohn's disease.

         16. Known bleeding disorders.

         17. Immediate or significant risk of toxic megacolon.

         18. Hypersensitivity to salicylates, aspirin, sulfasalazine or 5-ASA.

         19. Serum creatinine > 1.5 times the upper limit of the normal range.

         20. AST, ALT, total bilirubin or alkaline phosphatase > 2 times the upper limit of the
             normal range.

         21. Serious underlying disease other than UC which in the opinion of the investigator may
             interfere with the subject's ability to participate fully in the study.

         22. History of alcohol or drug abuse which in the opinion of the investigator may
             interfere with the subject's ability to comply with the study procedures.

         23. Stools positive for clostridium difficile.

         24. Pregnant or lactating women.

         25. Prior enrolment in the current study and had received study treatment.
Clinical trial NCT00658645 (phase 3, status: terminated)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: bifeprunox, placebo, quetiapine
SMILES: O=C1NC2=C(O1)C(=CC=C2)N1CCN(CC2=CC(=CC=C2)C2=CC=CC=C2)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Reason stopped: 
    interim analysis showed inadequate efficacy of bifeprunox
  
Eligibility criteria:

        Inclusion Criteria:

        Main inclusion criteria

          -  The subject has a primary diagnosis of schizophrenia

          -  The subject experiences clinically significant symptoms

          -  The subject's medication remained stable for 8 weeks prior to screening

          -  The subject is currently in the post-acute maintenance phase of his/her disease

        Exclusion Criteria:

        Main exclusion criteria

          -  The subject is at significant risk of suicide

          -  The subject is treatment resistant

          -  The subject has experienced an acute exacerbation within 8 weeks prior screening

          -  The subject is unlikely to comply with the protocol

          -  The subject has a current diagnosis or a history of substance abuse